Discovery Chemistry and Intellectual Property Manager
Tuesday, November 26th, 2019
The presentation will contain a summary of the proposed changes from the EU Review of pharmaceutical incentives and their possible impacts on small (and medium) size pharmaceutical companies and an example where the current European and US incentives are not successful (Superbugs vs new antibacterials/antibiotics)
· The value of IP for SMEs
· SMEs and the consequences of changes on them are often forgotten by legislators
· An overview of why the current incentives are not successful at bringing “life-saving” new antibacterials to market, what has been tried and what is being proposed and their possible effects on IP community.